MEDINDIA
English
हिन्दी
Español
français
中文
Email
Ixekizumab is administered by subcutaneous injection. It should be given under the guidance and supervision of a healthcare professional.
Patients may self-inject after taking proper training in subcutaneous injection technique using the autoinjector or prefilled syringe.
Injection should be taken at a different anatomic location (such as upper arms, thighs or any quadrant of abdomen) than the previous injection.
Ixekizumab should not be injected in the areas where the skin is tender, bruised affected by psoriasis. Injection in the upper, outer arm may be performed by a healthcare provider.
Before injection, remove Ixekizumab autoinjector or prefilled syringe from the refrigerator and allow it to reach the room temperature (30 minutes) without removing the needle cap.
Inspect ixekizumab solution visually for any particulate matter and discoloration prior to administration. It is clear and colorless to slightly yellow solution.
Do not use if the injection contains visible particles, is discolored or cloudy (other than clear and colorless to slightly yellow).
Any unused product left in the autoinjector or prefilled syringe should be discarded.
Patients are instructed to inject the full amount (1 mL), which provides 80 mg of ixekizumab
Injection contains 80 mg/mL solution of ixekizumab.
The dose is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks for treating adult plaque psoriasis.
• If there is an allergy to ixekizumab
• Patients below 18 years
Patients may self-inject after taking proper training in subcutaneous injection technique using the autoinjector or prefilled syringe.
Injection should be taken at a different anatomic location (such as upper arms, thighs or any quadrant of abdomen) than the previous injection.
Ixekizumab should not be injected in the areas where the skin is tender, bruised affected by psoriasis. Injection in the upper, outer arm may be performed by a healthcare provider.
Before injection, remove Ixekizumab autoinjector or prefilled syringe from the refrigerator and allow it to reach the room temperature (30 minutes) without removing the needle cap.
Inspect ixekizumab solution visually for any particulate matter and discoloration prior to administration. It is clear and colorless to slightly yellow solution.
Do not use if the injection contains visible particles, is discolored or cloudy (other than clear and colorless to slightly yellow).
Any unused product left in the autoinjector or prefilled syringe should be discarded.
Patients are instructed to inject the full amount (1 mL), which provides 80 mg of ixekizumab
Dosage & When it is to be taken
Ixekizumab injection is given subcutaneously by autoinjector and by prefilled syringe.Injection contains 80 mg/mL solution of ixekizumab.
The dose is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks for treating adult plaque psoriasis.
When it is not to be taken (Contraindications)
Ixekizumab should not be used in patients:• If there is an allergy to ixekizumab
• Patients below 18 years
